Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 10 art units • 19 examiners • 0 of 21 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Alexion Pharmaceuticals Inc. maintains a substantial presence in the Biotechnology & Pharmaceuticals technology area with 21 pending office actions. These actions are being reviewed by 18 distinct examiners, showing a broad but slightly more concentrated prosecution strategy compared to other large portfolios. The work is distributed across 9 distinct art units, which indicates that the company's pharmaceutical developments are being evaluated across a wide range of specialized biological and chemical categories within the patent office.
The busiest examiner for the portfolio is SZPERKA, MICHAEL EDWARD, who is currently managing 3 pending office actions. While there are 21 total pending actions, the involvement of 18 distinct examiners means that most cases are being handled by different individuals. This distribution helps mitigate the risk associated with any single examiner's decision-making process. However, the 9 distinct art units suggest that the company must still manage a complex array of examination standards. Practitioners should focus on the 3 pending actions under SZPERKA, MICHAEL EDWARD as a key area of concentration.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (14%) |
| §103 only | 6 (29%) |
| §112 only | 3 (14%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 4 (19%) |
| Multi-statute (no §101) | 4 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 3 | 62.9% | +36.8% |
| CONSTANTINE, CHARLES Z | 1 | 58.9% | +49.2% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| SVEIVEN, MICHAEL CAMERON | 1 | 37.5% | +47.9% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| HAM, JIEUN | 1 | 50.0% | +8.8% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | BAUER, BRIANNA LEE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 59d overdue |
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | — |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | — |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| 18032973 | METHOD OF CONTROLLING TOTAL SIALIC ACID CONTENT (TSAC) DURING MANUFACTURING OF ALKALINE PHOSPHATASE | RAMIREZ, DELIA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | RONEY, CELESTE A | 51d overdue |
| 18018936 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | SZPERKA, MICHAEL EDWARD | 17d overdue |
| 17784025 | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | SZPERKA, MICHAEL EDWARD | 8d overdue |
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | — |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 4 |
| 1612 | 1 |
| 1658 | 1 |
| 1643 | 1 |
| 1652 | 1 |
| 1759 | 1 |
| 1677 | 1 |
| 1674 | 1 |
| 1685 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — | §101§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | BAUER, BRIANNA LEE | — | §112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | — | §101§102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | — | §102§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | RONEY, CELESTE A | 1612 | §102§103§112DP | Final Rejection | 51d overdue | Pending | Jan 25, 2024 |
| 18577912 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS | HAM, JIEUN | — | §102§112DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | — | §103§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18505022 | PREPARATION OF FACTOR XA DERIVATIVES | SZPERKA, MICHAEL EDWARD | — | DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 38d overdue | Pending | Jul 07, 2023 |
| 18032973 | METHOD OF CONTROLLING TOTAL SIALIC ACID CONTENT (TSAC) DURING MANUFACTURING OF ALKALINE PHOSPHATASE | RAMIREZ, DELIA M | 1652 | §102§103§112Other | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18018936 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | SZPERKA, MICHAEL EDWARD | 1641 | §112Other | Final Rejection | 17d overdue | Pending | Jan 31, 2023 |
| 18010076 | METHODS FOR TESTING ANDEXANET POTENCY | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 5d overdue | Pending | Dec 13, 2022 |
| 17952897 | METHOD FOR MEASURING THE PROTEASE ACTIVITY OF C3 AND C5 CONVERTASE OF THE ALTERNATIVE COMPLEMENT PATHWAY | MARCSISIN, ELLEN JEAN | 1677 | §103 | Final Rejection | — | Pending | Sep 26, 2022 |
| 17849793 | ANTI-C5A ANTIBODIES | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 1685 | §101§103§112Other | Final Rejection | 59d overdue | Pending | Jun 10, 2022 |
| 17784025 | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | SZPERKA, MICHAEL EDWARD | 1641 | §103Other | Final Rejection | 8d overdue | Pending | Jun 09, 2022 |
| 17738131 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | KIM, YUNSOO | 1641 | §112DP | Final Rejection | 19d | Pending | May 06, 2022 |
| 17612368 | METHODS OF TREATING VITILIGO USING AN ANTI-C5 ANTIBODY | TAYLOR, LIA ELAN | 1641 | §103Other | Non-Final OA | — | Pending | Nov 18, 2021 |
| 17421511 | METHODS FOR PREPARING AMMONIUM TETRATHIOMOLYBDATE | SAWYER, JENNIFER C | 1691 | §103 | Non-Final OA | — | Pending | Jul 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial